In April 2024, Evernorth Health Services in the US announced that a biosimilar of AbbVie’s Humira ( adalimumab) will be available for US$0 out of pocket for eligible patients of its specialty pharmacy, Accredo. This announcement follows the news that prescriptions for adalimumab biosimilars have spiked to 36% after leading pharmacy benefit manager CVS Caremark removed the branded reference product from its major national commercial formularies in January 2024.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
-
Biosimilars
News
- EMA recommends approval of biosimilar bevacizumab Avzivi
- FDA approves first interchangeable aflibercept biosimilars to treat macular degeneration
- FDA approves ustekinumab trastuzumab, and tocilizumab biosimilars
- Update of biosimilars approved by Health Canada in 2023
Research
- Unveiling key clinical findings for denosumab biosimilar candidates
- Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
- Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
- Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
General
- Challenges and progress in the registration of biosimilars in Latin America
- Canada's path to biosimilar adoption and healthcare accessibility: insights from British Columbia
- Disruption in the US adalimumab market
- Addressing the persistent gap in Medicare access to Humira biosimilars
- MORE EDITORIAL SECTIONS
- Search
Post your comment